- Open
- 4.45
- High
- 4.45
- Low
- 3.72
- Close
- 3.75
- Change
- -0.75 (-16.85%)
- Volume
- 781,442
| 22 Jul 2026 | 07:00:03 | Thermo Fisher CDMO selected for Kapiglucagon pro |
| 25 Jun 2026 | 13:20:57 | 2026 RESULT OF ANNUAL GENERAL MEETING |
| 25 Jun 2026 | 07:00:07 | ImmuPharma appoints Bachem for Kapiglucagon API |
| 24 Jun 2026 | 07:00:06 | University of Murcia research relating to P140 |
| 4 Jun 2026 | 07:10:09 | Incanthera plc – Corporate Update & Board Changes |
| 10 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2014 |
ImmuPharma plc is a pharmaceutical company focused on the development and commercialization of novel drugs to treat serious medical conditions. It operates through collaborations with research institutions, such as the CNRS in France, and manages the clinical development of drug candidates. The company seeks partnerships to advance its product pipeline and maintains a lean corporate structure to control costs. ImmuPharma serves patients, healthcare professionals, and payers primarily in the pharmaceutical sector.
| 22 Jul 2026 | 07:00:03 | Thermo Fisher CDMO selected for Kapiglucagon pro |
| 25 Jun 2026 | 13:20:57 | 2026 RESULT OF ANNUAL GENERAL MEETING |
| 25 Jun 2026 | 07:00:07 | ImmuPharma appoints Bachem for Kapiglucagon API |
| 24 Jun 2026 | 07:00:06 | University of Murcia research relating to P140 |
| 4 Jun 2026 | 07:10:09 | Incanthera plc – Corporate Update & Board Changes |
| 10 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2014 |
ImmuPharma plc is a pharmaceutical company focused on the development and commercialization of novel drugs to treat serious medical conditions. It operates through collaborations with research institutions, such as the CNRS in France, and manages the clinical development of drug candidates. The company seeks partnerships to advance its product pipeline and maintains a lean corporate structure to control costs. ImmuPharma serves patients, healthcare professionals, and payers primarily in the pharmaceutical sector.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £336m | -0.4% | |
| £43m | — | |
IMMImmupharma PLC | £16m | +1.1% |
| £13m | -0.0% | |
| £12m | +0.5% | |
| £4m | +0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £336m | -0.4% | |
| £43m | — | |
IMMImmupharma PLC | £16m | +1.1% |
| £13m | -0.0% | |
| £12m | +0.5% | |
| £4m | +0.8% |
